Objectives: The introduction of HAART leads to control of HIV replication to less than 50 copies/ml, similar to levels in 'elite controllers'. Low-level viral replication may be one of the contributing factors to persistent immune activation/inflammation in HAARTtreated individuals. There are still gaps in our knowledge of whether low-level replication persists in systemic versus mucosal sites.
Introduction
Currently available HAART regimens can control HIV replication to less than 50 copies/ml and improve clinical outcomes [1] . The development of more sensitive HIV RNA assays has enabled detection of persistent viral replication in HAART recipients, but the clinical importance of low-level viremia is not currently understood [2] . Persistent low-level virus replication may contribute to ongoing immune activation/inflammation, and to non-HIV comorbidities including cardiovascular disease, bone disease, and neurocognitive decline [3, 4] .
Some HIV-infected individuals control HIV replication to less than 50 copies/ml without HAART [5] . These individuals, termed 'elite controllers', represent less than 1% of participants in most HIV cohorts. 'Elite controllers' often have innate [e.g. natural killer (NK) cell] and adaptive (e.g. HIV-specific CD8 þ T-cell) immune responses that contribute to the control of viral replication [6] . In addition, various host genetic factors are associated with viral control in 'elite controllers', including polymorphisms of CCR5, number of copies of the CCL3L1 gene, and specific HLA haplotypes [7] . The level of activation of HIV-specific CD4 þ and CD8 þ T cells has been shown to be elevated in 'elite controllers' relative to HAART recipients and HIV-uninfected controls, which may reflect ongoing T-cell responses stimulated by low-level viral replication [8] .
Few studies have compared the level of viremia in 'elite controllers' with that found among patients on suppressive HAART regimens [9, 10] . We addressed this question in the Women's Interagency HIV Study (WIHS), the largest prospective cohort study of HIV-infected and uninfected women in the United States. In addition to evaluating low-level plasma viremia among 'elite controllers' and a matched group of HAART-suppressed women, WIHS provided the unique opportunity to evaluate viral load in cervical-vaginal lavage (CVL) fluids of these patients. To our knowledge, there have been no studies to date that have determined and compared CVL viral load, using highly sensitive methods, among 'elite controllers' and HAART-suppressed participants.
Methods
WIHS enrolled 2054 HIV-infected and 569 uninfected women during 1994-1995. Another 737 HIV-infected and 406 uninfected women enrolled during 2001-2002 [11, 12] . For this analysis, the study population consisted of 33 'elite controllers' and 33 matched HAART recipients. 'Elite controllers' were HIV-infected, antiretroviral (ARV)-naive individuals with plasma viral loads less than 80 copies/ml (assay available at time of analysis) for at least 2 years. One viral blip (80-1000 copies/ml) was allowed during this 2-year interval. HAART recipients were those with viral loads 80 copies/ml or less for at least 2 years. We used propensity-score methods to match HAART recipients to 'elite controllers' on age, race, BMI, hepatitis C virus (HCV) antibody status, CD4 þ T-cell count, and study visit. We selected for testing at least three visits per person during the phenotypic period: the start, end, and alternating visits for each 'elite controller', and the start, end, and median visit for each HAART recipient. We selected CVL samples from 20 HIV-positive viremic patients who did not report using HAART to evaluate the performance of the viral load assay on CVL samples.
Longitudinal plasma and CVL samples were tested for HIV RNA levels using the Food and Drugs Administration-approved isothermal TC-TMA assay (Aptima; Gen-Probe, San Diego, California, USA). This assay is used to detect very early HIV infection in both blood donor screening and clinical diagnostic settings [13] . The assay utilizes 0.5 ml of plasma, and in this study was performed in quadruplicate, testing a total of 2.0 ml of plasma or CVL samples. Replicate testing allows for an improved lower detection limit of approximately 1 copy/ ml, compared with a 50% detection limit of 3.6-14 copies when the assay is performed in singlet. The assay results are reported as a signal/cut-off (S/Co) ratio. The range of the ratio is 0-30, with an S/Co more than 1.0 classified as HIV RNA 'positive'. Panels consisted of HIV-1 clade B virions spiked into plasma and CVL samples were prepared by the NIAID AIDS Clinical Trials Group Viral Quality Assurance (ACTG VQA) laboratory to establish the limits of detection and dynamic range for quantitation of HIV by the replicate TC-TMA assay as well as for quality control during the course of clinical sample testing.
Comparisons of baseline characteristics between phenotypic groups were conducted using x 2 analysis or Fisher's exact tests for categorical variables and Wilcoxon rank tests for continuous measures. Longitudinal data were analyzed using linear mixed models incorporating leftcensoring [14] for the continuous outcomes and GEE models for the categorical outcomes. To normalize distributions, plasma and CVL S/Co data were transformed by base 10 logarithms. Nonparametric trend analyses over time utilized Mann-Kendall tests. All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, North Carolina, USA) and graphics were generated using R package version 2.15.2.
The groups were well matched with respect to age, race/ ethnicity, HCV status, and BMI at baseline. The median evaluation period was 4 years for 'elite controllers' and 4.5 years for HAART recipients (P >0.05 for all matching factors). Figure 1a presents the correlation of average S/Co values of four replicate TC-TMA assays with estimated viral loads in serially diluted standards prepared by the ACTG VQA laboratory and tested under code. The results demonstrated a lower limit of sensitivity of 1-3 copies/ml and a dynamic range up to 30-50 copies/ml with a highly significant (r ¼ 0.90 P ¼ <0.0001) correlation between input viral levels and average S/Co of the replicate TC-TMA assay (Fig. 1a) . The low-level viral load quality control panel demonstrated excellent assay specificity (no signal in replicate TC-TMA testing of nonspiked QC samples), consistent high S/Co values in the 50 copy/ml QC samples, and intermediate reactivity in the 5 copy/ml QC samples. Spiking of nondiluted CVL samples from HIV-uninfected control women with 50 and 500 HIV copies/ml yielded S/Co values ranging from 6.9 to 8.2 and 21.9 to 23.0, respectively. CVL samples spiked with 5 HIV copies/ml and nonspiked CVL samples yielded consistently negative results (S/Co values <0.24). We also tested CVL samples from 20 HIV viremic WIHS women who were not on HAARTat the time of sampling and had plasma viral loads selected to be representative of the distribution of plasma viremia in untreated women. All except one of these samples tested positive for HIV RNA by TC-TMA, with S/Co values ranging from 0.15 to 27 ( Fig. 2a ).
TMA assay performance

HIV RNA levels in plasma and cervical-vaginal lavage
We evaluated 93 plasma samples from 32 'elite controllers' and 92 plasma samples from 31 HAART recipients who had valid plasma TC-TMA results. The median (interquartile range) plasma viral load S/Co for 'elite controllers' was 10.5 (3.9-21.1), which was significantly (P <0.001) higher than the S/Co for HAART recipients [2.0 (1-4.9)] (Fig. 1b) . The proportion of plasma samples that were undetectable (at the assay cut-off of 1.0 copies) was significantly lower among 'elite controllers' than among HAART recipients (12 versus 45%, P <0.001). Plasma S/Co levels were stable during the entire period of longitudinal analysis among elite controllers (slope ¼ 0.00, P ¼ 0.93), whereas levels decreased slightly but not significantly in HAART recipients (slope ¼ À0.01, P ¼ 0.30; Fig. 1c ).
Ninety six CVL samples from 32 'elite controllers' and 93 CVL samples from 31 HAART recipients had valid CVL TC-TMA results (based on reactive internal control results indicating no inhibition). The majority of CVL samples had undetectable HIV RNA based on the average S/Co of replicates below the assay cut-off of 1.0 (Fig. 2b) ; however, S/Co values of individual TC-TMA determinations were above the assay cut-off of 1.0 for 12 (13%) elite CVL samples and four (4%) HAART CVL samples. The proportion of CVL replicate samples with S/Co more than 1.0 from 'elite controllers' was not significantly different from HAART recipients (P ¼ 0.12).
Discussion
Utilizing the replicate TC-TMA assay approach, we found that 'elite controllers' demonstrated higher frequency of low-level plasma viral loads compared with HAART recipients with undetectable viral loads in standard assays. Among 'elite controllers', the low levels of plasma virus were stable, whereas there was a nonsignificant decline in HAART recipients over the 4-year study period. In contrast, we did not find significantly elevated S/Co ratios in CVL specimens from 'elite controllers' compared with HAART recipients. Of note, detectable levels of HIV RNA were documented in CVL samples from viremic, untreated patients, validating the sensitivity of the TC TMA assay for CVL samples.
These findings are consistent with previously published studies from two well defined 'elite controller' cohorts. A study by Hatano et al. [10] utilized the same TC-TMA assay as our study and found a mean HIV RNA S/Co of 9.3 among elite versus 6.3 among HAART recipients. Although their finding was not statistically significant among the 'elite controllers', the investigators found that 98% of the samples had detectable RNA, a higher proportion than among HAART recipients. In another study of 'elite controllers' by Pereyra et al. [6] , persistent low-level HIV correlated with levels of HIV-specific antibody. A study by Dinoso et al. [9] reported that six 'elite controllers' with detectable viral load demonstrated a higher median viral load copy number (25 copies/ml) compared with nine HAART recipients with detectable viral loads (2 copies/ml).
This low level of HIV detected in 'elite controllers' may contribute to immune activation and progressive T-cell loss. Other immune factors may also drive persistent immune activation/inflammation, including coinfecting pathogens (e.g. cytomegalovirus) and products of microbial translocation from the gastrointestinal tract. We have previously demonstrated that 'elite controllers' show higher levels of CD8 þ T-cell activation compared with HAART recipients [15] . Persistent immune activation may contribute to non-HIV comorbidities including cardiovascular disease. The implication for this finding is the potential benefit of antiretroviral treatment for 'elite controllers' [16] . Indeed, the ACTG has initiated a treatment trial for 'elite controllers' with the primary outcome being the impact of HAART on immune activation.
In contrast to the CVL samples of the HIV-positive viremic women off HAART, we observed the virtual absence of viral RNA in serial CVL specimens from both 'elite controllers' and HAART recipients. These results suggest there is probably a very low risk of secondary sexual transmission of HIV from 'elite controllers' and HAART recipient women who are aviremic, which is consistent with studies documenting absence of HIV in semen from HAART recipients with controlled viremia and with clinical studies documenting efficacy of HAART in reducing heterosexual transmission of HIV [17] .
This study demonstrates that one can gain insights into the pathogenic significance of persistent HIV replication by comparing 'elite controllers' to HAART recipients. These individuals provide a unique opportunity to evaluate how natural control of HIV (i.e. in the absence of antiretroviral therapy) impacts the host immune system and subsequent disease outcomes relative to treatment that is observed in HAART-suppressed patients. This study provides potential new insights into the design of trials to define the role of low-level HIV replication contributing to non-HIV comorbidities and the potential value of treating 'elite controllers' to further suppress viral replication to, or potentially even below, levels seen in HAART-suppressed patients.
